INTRODUCTION
Platelet activation and blood coagulation are highly reciprocally interacting processes and both essential for hemostasis and thrombosis. Activated platelets support and steer the coagulation process by at least four mechanisms, i.e. by releasing coagulation factors like factor V and XIII; by exposing the procoagulant phospholipid phosphatidylserine (PS) at their outer surface to support thrombin generation; by providing a scaffold for the formation of fibrin fibers; and by causing retraction of the fibrin clot. 1, 2 In a growing thrombus, aggregated and procoagulant platelets form two distinct populations, 3, 4 which is at least partly explained by the high Ca 2+ response required for PS exposure and coagulation factor binding, and by the calpain-dependent closure of active α IIb β 3 integrins after PS exposure, thus antagonizing inclusion of procoagulant platelets into a platelet aggregate. 5, 6 However, another platelet population has also been identified, usually referred to as coated platelets, 7 which may partly overlap with the two other platelet populations described above. 3 In the initial paper, Dale and co-workers describe COAT platelets (later renamed as coated platelets) as a population of platelets arising after combined stimulation with collagen and thrombin, which bind α -granule proteins, including factor V, fibrinogen, von Willebrand factor, thrombospondin, fibronectin and α 2 -antiplasmin, in a transglutaminase-dependent way via the formation of covalent serotonin conjugations. 8 Since the first description, coated platelets are invariably considered as platelets formed after combined stimulation of collagen receptors (e.g. with collagen, convulxin or collagen-related peptide) and thrombin receptors (e.g. with thrombin or thrombin receptoractivating peptides), but in literature there is no uniform definition of this platelet population.
The Dale group has been using the retention of secreted proteins, including platelet-derived serotonin-derivatized proteins, factor V and tissue factor pathway inhibitor on the platelet surface as a characteristic. [9] [10] [11] Another definition has been used by the Jobe group, i.e.
platelets containing high surface levels of fibrinogen, likely through cross-linking via the transglutaminase factor XIII. 12 However, in recent years, it is becoming common practice to consider coated platelets more or less equivalent to fibrinogen binding platelets or PSexposing platelets. For instance, platelet subpopulations in patient studies have recently been characterized using biotin-fibrinogen. [13] [14] [15] This ambiguity in definition and described properties raises questions whether coated platelets form a platelet subpopulation -after collagen/thrombin receptor stimulation -that is distinguishable from that of fibrinogen and/or PS-exposing platelets and whether they fulfill a specific function.
In the present paper, we used a specific transglutaminase substrate, i.e. the α 2 -antiplasmin-derived peptide Rhod-A14, as a tool to identify transglutaminase-active platelets.
We compared the binding of Rhod-A14 to platelets, stimulated via the collagen and thrombin receptors, with other platelet activation markers. The results indicate that transglutaminase activity partly overlaps but is not identical to PS exposure. We furthermore provide evidence that the transglutaminase activity along with integrin α IIb β 3 activation is required for fibrin anchoring at the platelet surface and star-like platelet-dependent fibrin formation.
METHODS
Extended materials and methods are available in the online-only Supplement.
Blood Collection and Platelet Preparation. Experiments were approved by the local Medical
Ethics Committees. Blood was taken from healthy volunteers and from a patient with Glanzmann's thrombasthenia, with established deficiency in integrin α , abbreviated as F13a1 -/-) 17 were bred on a mixed 129Sv/CBA background and were compared to F13a1 +/+ mice of the same backgrounds (Harlan Laboratories). Murine blood was taken on trisodium citrate for wholeblood flow experiments; other blood samples were taken on acid-citrate-dextrose anticoagulant to isolate washed platelets, as described.
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Flow Cytometric Platelet Analyses. Washed human or mouse platelets (5×10 7 /ml) were preincubated with indicated inhibitors or Me 2 SO vehicle for 10 minutes, and stimulated in the presence of 2 mM CaCl 2 . In the activations, 0.2 mM Gly-Pro-Arg-Pro (GPRP) was added to prevent formation of large fibrin fibers. 19 Platelet sub-populations were distinguished by probing with Rhod-A14 (10 μ g/ml), AF647-annexin A5 (1:200), AF488-factor V (20 nM), OG488-factor Xa (100 nM), AF647-fibrinogen (100 µg/ml) and FITC-PAC-1 (1.25 μ g/ml).
After staining for 5 minutes, samples were analyzed with a FACScan flow cytometer (BD Accuri Cytometer). 6 In a separate set of experiments, reconstituted PRP was activated with tissue factor (2 pM) and CaCl 2 (16.7 mM) in the presence of GPRP (2 mM) at 37 °C, after which samples were taken for fluorescent labeling. Analysis was by flow cytometry as above.
Thrombin Generation. Thrombin generation was measured in citrate-anticoagulated human PRP as described before. 20 First-derivative curves were converted into curves of nanomolar thrombin concentrations using a calibrator for human α -thrombin. 21 All analyses were in triplicate.
Thrombus Formation on Collagen under Flow. Whole blood thrombus formation on collagen was assayed in the absence or presence of coagulation, as described before. 22 Thrombi formed on collagen were post-stained with Rhod-A14 and AF647-annexin A5 in Hepes buffer, supplemented with CaCl 2 (2 mM) and heparin (1 unit/ml). Phase-contrast and fluorescence images were captured and analyzed with Metamorph software version 7.5.0.0 (MDS Analytical Technologies), as detailed elsewhere. 23 Statistical difference of quantitative colocalization of two-color confocal images was determined using the ZEN software 2010 B SP1. Star-like fibrin formation was assessed as described in the online-only Supplement.
Statistics. Significance of differences between control and experimental groups as well as changes between groups over time was determined by 1-way or 2-way analysis of variance followed by a Bonferroni post-hoc test. Distribution of fibrin fibers was evaluated by χ 2 analysis.
24 P values <0.05 were considered to be significant.
RESULTS

Coated platelets as transglutaminase active platelets
First we assessed the appearance of a coated platelet population following the initial description of formation of a transglutaminase-dependent protein coat on the platelet surface. 8 Therefore, we synthetized a fluorescent-labeled 14-amino acid transglutaminase peptide substrate, GNQEQVSPLTLLK(C-tetramethylrhodamine)W (Rhod-A14), derived from the N-terminal peptide sequence of α 2 -antiplasmin. This peptide contains a glutamine at Q 3 , which serves as a transglutamination site for cross-linking to available ε-amino lysine residues. 25 The Rhod-A14 peptide was site-specifically labeled with a tetramethylrhodamine group, which did not interfere with its substrate properties. Control experiments indicated that the peptide could act as a substrate for both tissue-type transglutaminase and factor XIIIa (not shown, but see below).
Flow cytometric analysis indicated that the Rhod-A14 label bound to a population of convulxin/thrombin-activated platelets, which was gradually formed after about 15 minutes of activation and increased until 60 minutes to about 50% Rhod-A14 positive platelets ( Figure 1A+B ). This markedly differed from the appearance of PS-exposing platelets analyzed by annexin A5 binding, which was already maximal after 15 minutes. Two-color flow cytometry indicated that the Rhod-A14 positive platelets represented a discrete subpopulation: these platelets were in majority PS positive (binding of annexin A5), but had inactive α Figure 1D ). In sharp contrast, neither the addition of factor XIII nor these inhibitors affected the PS exposure evoked by convulxin/thrombin ( Figure 1E ). Taken together, these results indicate that the transglutaminase-active, Rhod-A14 positive platelets form as a subpopulation of PS-exposing platelets after collagen/thrombin receptor stimulation.
Coated platelets as high fibrinogen-binding platelets
Platelet activation with convulxin/thrombin has been demonstrated to result in a fraction of platelets displaying high fibrinogen binding, which has also been referred to as coated platelets. 12 In our hands, after 5 minutes of stimulation with convulxin/thrombin, the binding of fluorescently labeled fibrinogen reached a maximal high level, which occurred faster than the appearance of PS-exposing platelets (Suppl. Figure 3A- Figure 3A ,D). Interestingly, the fibrinogen binding per platelet slightly declined upon prolonged incubation with convulxin/thrombin (Suppl. Figure 3B ), whilst the fraction of fibrinogen-positive platelets remained stable ( Figure 2A ). This suggests that a portion of α IIbβ3 integrins on the surface Cvx/Thr activated platelets can close in time, which was in agreement with labelling studies using PAC-1 mAb (Suppl. Figure 1D ). Dual color flow cytometry indicated that Rhod-A14 binding platelet fraction was a subpopulation of the high fibrinogen-binding cells (Suppl. Figure 1C ).
Coated platelets as procoagulant, PS-exposing platelets
In recent papers, coated platelets have been proposed to be equivalent to coagulation factor binding platelets or PS-exposing platelets. 7, 26 To investigate this in more detail, we compared the fractions of convulxin/thrombin-stimulated platelets that bind AF647-annexin A5, OG488-factor Xa, FITC-factor V or Rhod-A14. As shown in Figure 2A , the appearance of a platelet population with binding sites for annexin A5, factor V and factor Xa occurred fast with similar kinetics, whereas the formation of Rhod-A14-binding platelets was considerably slower. Pre-incubation with transglutaminase inhibitor K9-DON did not influence the binding of annexin A5 nor the coagulation factors, but greatly impaired the binding of Rhod-A14
( Figure 2B ). In agreement with this result, the presence of K9-DON did not influence the process of thrombin generation in PRP ( Figure 2C-D) . This indicated that the transglutaminase activity of platelets was independent of the interaction of factor Va and Xa, and of subsequent platelet-dependent thrombin generation, which relies on this interaction.
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Coated platelets as fibrin-forming platelets
Our earlier work demonstrated that platelet stimulation with strong agonists leads to integrin α IIb β 3 activation, followed by PS exposure and calpain-dependent closure of the integrin. 6 Furthermore, we found that PS exposure instigates the formation of a fibrin network linked to the platelet surface. 27 Here, we reinvestigated this by assessing the determinants of high fibrin(ogen) binding and PS exposure of platelets in tissue factor-activated blood plasma. For this purpose, plasma samples were defibrinated to prevent massive clot formation, 19 and then reconstituted with washed platelets. After triggering coagulation with tissue factor and calcium, the majority of platelets showed rapid and sustained high fibrinogen binding, followed by the appearance of a platelet subpopulation with PS exposure, as determined by dual-labeling with OG488-fibrinogen and AF647-annexin A5 ( Figure 3A ). Detailed analysis indicated that only part of the high fibrinogen-binding platelets exposed PS, whereas the majority of PS-exposing platelets showed high fibrinogen binding ( Figure 3B ). Again was the high fibrin(ogen) binding dependent on the presence of thrombin, since these platelets stained with an anti-fibrin Ab and the thrombin inhibitor hirudin substantially suppressed fibrinogen binding (data not shown).
High fibrin(ogen) binding of a subpopulation of the PS-exposing cells was observed not only with labeled fibrinogen, but also with an antibody (FITC-WAK) recognizing platelet-bound fibrin(ogen) (Suppl. Figure 4A+B ). This is in agreement with the results with washed platelets described above that, in the presence of thrombin, the high fibrin(ogen)
binding is regulated differently from PS exposure.
Staining of the tissue factor-triggered platelets in plasma with FITC-PAC-1 mAb, recognizing activated integrin α IIb β 3 , pointed to rapid integrin activation that subsequently declined ( Figure 3C ). However, when these platelets were stained for the integrin β 3 -chain, fluorescence remained high (not shown), indicating that the integrin was still present and accessible at the platelet surface. In comparison to integrin activation, exposure of PS rose slower in time ( Figure 3C ). Similarly as reported before, 6 the majority of PAC-1 mAb positive platelets were annexin A5 negative, while the annexin A5 positive platelets were mostly PAC-1 mAb negative ( Figure 3D ). Dot plots of platelets in plasma, double labeled with AF647-annexin A5 and FITC-PAC-1 mAb, confirmed that most PS-exposing cells were unable to bind PAC-1 mAb (Suppl. Figure 4C ). Also in this plasmatic condition, a population of PS-positive platelets showed a mean 2.8-fold increase in Rhod-A14 fluorescence above background. Taken together, these results suggest that the high fibrin(ogen)-binding platelet fraction contains a fibrin coat, which precedes PS exposure and primes for binding or Rhod-
A14.
Transglutaminase activity in platelet thrombus formation under flow conditions
To investigate where coated platelets localize in platelet thrombi, we performed whole blood perfusion experiments over a collagen surface under arterial shear conditions. Double staining with Rhod-A14 and AF657-annexin A5 indicated that, under non-coagulant conditions (with thrombin inhibitor present), Rhod-A14 binding was restricted to a subpopulation of PS-exposing platelets ( Figure 4A ). Co-localization analysis demonstrated that the majority of Rhod-A14 positive pixels also stained with AF647-annexin A5. Addition of K9-DON completely blocked the Rhod-A14 staining, but did not affect PS exposure.
Zoomed images indicated that the Rhod-A14 labeling was confined to balloon-shaped, PSexposing platelets, but often did not label the complete platelet ( Figure 4A , overlay and bar graph). When thrombi were allowed to form on collagen under coagulant conditions (recalcification without thrombin inhibitor), this resulted in increased Rhod-A14 staining, which again was antagonized by K9-DON. Also a higher AF637-annexin A5 staining was found, which was unaffected by K9-DON ( Figure 4B ). Under these coagulant conditions, PSexposing balloon-shaped platelets still bound Rhod-A14, while the majority of the Rhod-A14 label was located on fibrin fibers.
Next we performed flow experiments with F13a1 +/+ or F13a1 -/-mouse blood over collagen under both non-coagulant and coagulant conditions. In the non-coagulant condition, citrate anti-coagulated whole blood was recalcified in the presence of PPACK to block thrombin generation while physiological calcium and magnesium levels were restored. Under these conditions factor XIII activation is averted (no thrombin), whereas tissue type transglutaminase can be active (physiological calcium levels). The thrombi obtained with blood from F13a1 +/+ or F13a1 -/-mice were similar in size under these conditions with no more than low Rhod-A14 labeling ( Figure 5A , B). These data suggest no major role for tissue To investigate the formation of fibrin fibers, blood from F13a1 +/+ and F13a1 -/-mice was prelabeled with AF647-fibrinogen and perfused over a collagen surface under coagulating conditions. Detailed examination by confocal fluorescence microscopy indicated that, for wild-type thrombi, fibrin fibers were connected to the platelet surface and oriented to all directions ( Figure 7A , B). This staining pattern resembled the star-like formation of fibrin at the platelet surface observed before. 27 In wild-type thrombi treated with integrin blocker tirofiban and also in factor XIII-deficient thrombi, the orientation of fibrin fibers from platelets was typically more frequent in the direction of the blood flow ( Figure 7A+B ). A similar shift in orientation of fibrin fibers was observed on human thrombi formed with whole blood from a Glanzmann's thrombasthenia patient (Suppl. Figure 5) . Markedly, the addition of tirofiban to factor XIII-deficient blood nearly completely blocked the star-like orientation of fibrin fibers, but still allowed the plasmatic formation of fibrin fibers rectilinear with the blood flow.
In subsequent experiments, platelet-dependent star-like fibrin formation was examined on the level of single platelets by using a previously established method. 27 Whereas on the surface of control platelets a star-like fibrin network was formed upon post-perfusion with normal pool plasma, the orientation of the fibrin fibers was significantly altered upon post-perfusion with factor XIII-deficient plasma ( Figure 7C+D ). A similar shift in orientation of fibrin fibers was observed on the surface of Glanzmann's thrombasthenia platelets. Postperfusion of Glanzmann's thrombasthenia platelets with factor XIII-deficient plasma completely blocked fibrin formation during >20 minutes. However, rectilinear plasmatic fibrin formation did occur after ~30 minutes of plasma perfusion, but no platelet-dependent fibrin formation could be observed. A similar absence of platelet-dependent fibrin formation was seen upon addition of K9-DON to Glanzmann thrombasthenia platelets (P<0.001). In sum, these data indicate a non-redundant and synergistic role of the transglutaminase factor XIII and integrin α In contrast to washed platelets, Rhod-A14 binding platelets were much faster formed (minutes) during human whole-blood thrombus formation on collagen. This can be explained by a rapid availability of transglutaminases like human factor XIII in the blood plasma, but it may also point to a relatively slow externalization and/or activation of platelet-derived transglutaminases in the absence of plasma. Given that transglutaminases are broad-spectrum enzymes, cross-linking ε-(γ-glutamyl)lysine isopeptide bonds of multiple proteins, 33, 34 it can safely be assumed that Rhod-A14-binding platelets are covered (coated) with a large set of cross-linked proteins at their surface.
In our previous work we have shown that platelets act as a scaffold for star-like fibrin formation. 27 Here we provide evidence of a combined role of integrin α IIb β 3 and factor XIII in this process. In agreement with the results from others, 12 we find that murine factor XIII is dispensable for high fibrinogen binding and PS exposure. Although platelet-dependent fibrin fiber formation could still occur in blood from F13a1 -/-mice, -which points to dispensability of factor XIII for the formation of fibrin fibers as such -, we did observe a significant change in the attachment of fibrin fibers formed on the thrombus surface. Additional blockage of integrin α IIb β 3 led to a further shift from platelet-dependent star-like fibrin formation to platelet-independent fiber orientation rectilinear to the blood flow. Also in the human system the star-like fibrin fiber formation on the platelet surface was synergistically mediated by integrin α IIb β 3 activation (Glanzmann's thrombasthenia patient) and factor XIII activity. This functional redundancy of integrin α IIb β 3 and factor XIII might explain the poor correlation of the defect in α IIb β 3 with the bleeding tendency observed in Glanzmann's thrombasthenia patients. 35 Although earlier studies found tissue type transglutaminase to be present in human platelets, 8, 36 in more recent work it could not be detected on the platelet protein level.
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Interestingly, in mouse platelets tissue type transglutaminase (Tgm2) could be detected, albeit with a 25x lower expression in comparison to factor XIII (F13a). 28 Our present findings point to a predominant role of factor XIII and not of tissue type transglutaminase in both the human and murine systems, which is line with the recent studies. Recently, a role for platelet-derived FXIII was proposed in regulating anti-fibrinolysis by cross-linking α 2-antiplasmin to fibrin.
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Our present findings significantly extend this study by demonstrating a role for factor XIII earlier on in the process of hemostasis and thrombosis, i.e. by mediating the formation of a star-like coat of fibrin fibers on the platelet surface.
In sum we report the following mechanism for formation of coated, Rhod-A14-binding platelets: initial collagen/thrombin receptor-induced α IIb β 3 activation leads to fibrin(ogen) binding, which on PS-exposing platelets can be consolidated by factor XIII transglutaminase activity, and act as a scaffold for star-like platelet-driven fibrin fiber formation. Since many of these coated platelets still bind coagulation factors, they can in addition have a role in stimulating prothrombinase activity and thrombin generation leading to stabilization of the platelet-fibrin clot.
16. Rosado Active-site OG488-labeled human factor Xa and prothrombin as well as AF488-labeled bovine factor V(a) were prepared, as described. Other chemicals were from sources described before. In a separate set of experiments, reconstituted PRP was activated with tissue factor (2 pM) and CaCl 2 (16.7 mM) in the presence of GPRP (2 mM) at 37 °C, after which samples were taken for fluorescent labeling. Analysis was by flow cytometry as above.
SUPPLEMENTAL MATERIALS AND METHODS
Materials
Thrombin Generation. Thrombin generation was measured in citrate-anticoagulated human PRP. 9 The PRP was diluted with autologous PFP to a count of 1.5×10 8 platelets/ml. Samples were activated with convulxin (100 ng/ml) plus thrombin (4 nM) or vehicle for 15 minutes.
Aliquots (4 volumes) were transferred to a polystyrene 96-wells plate (Immulon 2HB, Dynex Technologies), already containing 1 volume of buffer C (20 mM Hepes, 140 mM NaCl, 5 mg/ml BSA and 6 pM tissue factor). Coagulation was started by adding 1 volume of buffer D (2.5 mM Z-GGR-AMC, 20 mM Hepes, 140 mM NaCl, 100 mM CaCl 2 and 60 mg/ml BSA).
First-derivative curves were converted into curves of nanomolar thrombin concentrations using a calibrator for human α-thrombin. 10 All analyses were in triplicate. 12 Statistical difference of quantitative colocalization of two-color confocal images was determined using the ZEN software 2010 B SP1.
Microscopic measurement of platelet-dependent star-like fibrin formation under flow.
Platelet-dependent star-like fibrin formation was measured as described before. 13 In brief, 
